Metrics Inc. Appoints Senior Director of Operations

Greenville, NC, February 02, 2013 --(PR.com)-- Metrics Inc. has appointed Joe Cascone as senior director of operations.

In his new role at Metrics, Cascone will manage the company’s commercial drug product manufacturing and packaging capabilities. He also is responsible for facility-related operations such as engineering, environmental health and safety, and security.

“Metrics has the expertise and resources to quickly move a product from development to commercialization, which appeals to clients for whom timing is everything,” said Phil Hodges, president. “As experienced and knowledgeable as Joe is, he’ll ensure that our manufacturing operations remain ahead of the competitive field in both quality and efficiency.”

This appointment represents a promotion for Cascone. He previously served as director of potent pharmaceutical development, managing Metrics’ potent and cytotoxic drug handling capabilities as well as its dedicated and segregated potent facility.

Cascone holds a bachelor’s of science degree in biology and chemistry from Virginia Tech and a master’s degree in business administration from East Carolina University. He is a member of the American Association of Pharmaceutical Scientists, the International Society for Pharmaceutical Engineering and the Forum for Pharmaceutical Professionals.

Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. They deliver proven scientific and operational excellence for solid oral dosage forms.

The company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.

Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods. Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.

Based in Greenville, N.C., Metrics Inc. proudly operates as a subsidiary of Mayne Pharma Group Limited. To learn more about our company, visit metricsinc dot com.